TES Pharma signs new research and development collaboration with Ecole Polytechnique Federale de Lausanne.
M2 EQUITYBITES-July 6, 2015-TES Pharma signs new research and development collaboration with Ecole Polytechnique Federale de Lausanne
(C)2015 M2 COMMUNICATIONS http://www.m2.com
TES Pharma, an emerging science-driven drug discovery company, has signed a new research and development collaboration with Switzerland-based Ecole Polytechnique Federale de Lausanne.
It was reported on Friday that the collaboration is aimed at novel small molecule modulators of the kynurenine pathway as therapies for metabolic disorders and age-related diseases. It bring together TES Pharma, a research-based biotech company led by Professor Roberto Pellicciari (scientific co-founder of Intercept Pharmaceuticals Inc) with state of the art research facilities in Corciano (Perugia) and long running experience in modulators of the kynurenine pathway and metabolic disorder drug discovery, with the Laboratory of Integrative and Systems Physiology (LISP) at EPFL, led by Professor Johan Auwerx (professor and Nestle chair in Energy Metabolism) pioneers in the role of NAD+ biosynthesis in metabolic disorders and ageing.
Professor Pellicciari said, 'Combining our respective expertise provides an exciting platform for novel drug discovery with a world leader in metabolic disorders and ageing. Taking forward small molecule therapies for these multi-faceted diseases requires detailed knowledge of the underlying basic biology, so we're very excited about the opportunity work with LISP and Professor Auwerx to develop new disease-modifying therapies for these disorders.'
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jul 6, 2015|
|Previous Article:||Kite Pharma collaborates with the Leukemia & Lymphoma Society.|
|Next Article:||Clas Ohlson plans new store opening in Ealing, London, UK in January 2016.|